Why Is Nano-Cap Aptorum Stock Rallying On Thursday?

Core Insights - Aptorum Group Limited's stock (APM) is experiencing significant trading activity, with a volume of 168.16 million shares compared to the average of 3.25 million shares [1] - DiamiR Biosciences Corp., Aptorum's merger partner, has received approval for its APOE Genotyping test from the New York State Department of Health [1][2] - The merger between Aptorum and DiamiR is expected to close in the fourth quarter of 2025, with DiamiR becoming a wholly owned subsidiary of Aptorum [4] Company Developments - DiamiR's approved APOE Genotyping test will be available for various biological samples, enhancing its market reach through CLIA certified and CAP accredited laboratories [2] - The approval of the APOE Genotyping test is seen as a significant advancement for risk assessment and personalized care strategies for cognitive decline [3] - Aptorum has regained compliance with Nasdaq's minimum bid price requirement, as confirmed in August [3] Stock Performance - APM stock has seen a substantial increase of 148.08%, reaching a price of $3.15 [4]